Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetic Studies of Tacrolimus in Transplant Patients
NCT01889758Phase 4Completed
- Sponsor
- University of Cincinnati
- Start
- Jun 2013
- Primary completion
- Jan 2016
- Modality
- RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of tacrolimus in kidney transplant rejection and Liver transplant rejection (3 arms), sponsored by University of Cincinnati. Primary endpoints: Comparison of bioequivalence between brand name prograf to generic Hi tacrolimus at Day 42, Comparison of bioequivalence between brand name prograf to generic Lo tacrolimus at Day 42 and 1 more. Started Jun 2013; status: completed.
02
Drugs
tacrolimus
03
Conditions
kidney transplant rejectionLiver transplant rejection
Beyond the preview
Go deeper on NCT01889758.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01889758.